Recardio

Regenerative Cardiac

  • About Us
    • Profile
    • Management
    • Boards
    • Awards
  • Science
    • Background
    • Rationale
    • Therapy
  • Clinical
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News Center

Jun 19 2019

Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolling and Recruiting in Global Centers

San Francisco, June 19, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in multiple European and US centers.

Read More

Written by Recardio · Categorized: Uncategorized

Jun 03 2019

First Closings of Series B Financing Round

San Francisco, June 3rd, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases, announced the first closings of its Series B financing round.

Read More

Written by Recardio · Categorized: Uncategorized

Mar 21 2019

Recardio presented at the Cell & Gene Therapy Conference in New York

San Francisco, March 21, 2019 – Recardio announced today that it presented at the Cell & Gene Therapy Conference in New York.

Read More

Written by Recardio · Categorized: Uncategorized

Jan 07 2019

Recardio at J.P. Morgan Conference 2019

San Francisco, January 07, 2019 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, today announced that it is participating in the 37thAnnual J.P. Morgan Healthcare Conference on January 7thin San Francisco.

Read More

Written by Recardio · Categorized: Uncategorized

Dec 13 2018

Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolled First Patients and Recruiting in Multiple Centers

San Francisco, December 13, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases,announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction has now enrolled the first patients and is now recruiting in multiple European centers. The remaining sites in Europe and in the US will join in the coming months.

Read More

Written by Recardio · Categorized: Uncategorized

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2021 · All Rights Reserved

Copyright © 2021 · Recardio on Genesis Framework · WordPress · Log in